PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目标是：确定曲拉平和吉西他滨联合治疗胆道和胆囊癌患者的客观有效率；评估曲拉平和吉西他滨联合治疗胆管和胆总管肿瘤患者的毒性和从毒性中恢复的情况；以及确定联合使用曲拉平和吉西他滨治疗胆道和胆囊癌患者的存活率和无进展存活率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives are to: determine the objective response rates for the combination of triapine and gemcitabine in patients with primary tumors of the biliary ducts and gall bladder; assess the toxicities and recovery from toxicities for patients with biliary duct and gall baldder tumors treated with the combination of triapine and gemcitabine; and determine the survival and progression free survival of patients with biliary and gall bladder tumors treated with combination of triapine and gemcitabine.